From Barchart: 2024-12-19 02:00:03

cbdMD, Inc. (NYSE American: YCBD) is a prominent player in the CBD industry, known for brands like cbdMD and Paw CBD. They also entered the functional mushroom market with ATRx Labs, competing in the wellness sector with innovative products.

Wall Street predicts cbdMD will report an EPS of -$0.45 for the upcoming quarter, down from the previous quarter’s -$0.15. Despite this, the company reduced its net loss by $19.1 million year over year, showing financial improvement.

Projected revenue for the quarter is approximately $4.81 million, slightly lower than the previous quarter’s $5.17 million. Despite this, cbdMD ended the fiscal year with a stronger cash position, indicating financial stability and potential for growth.

In the last quarter, cbdMD’s gross profit was $3.40 million with a cost of revenue at $1.77 million, showing a healthy margin. However, the operating income was negative at $382,028, resulting in an operating loss. The EBITDA was $1.06 million, reflecting efforts to enhance financial health.



Read more at Barchart:: cbdMD, Inc. (NYSE American: YCBD) Quarterly Earnin…